High Purity 99% Retatrutide Peptide Raw Powder For Laboratory Research Only

  Product Detail  

Brief Introduction of Retatrutide:

Retatrutide is a new type of multi-target peptide drug developed by Eli Lilly and Company of the United States, it is a triple receptor agonist of GLP-1R/GIPR/GCGR. Its core mechanism is to regulate the metabolic process by activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptors at the same time, and is used for the treatment of obesity and type 2 diabetes. The following are its key features:

Mechanism of Action and Molecular Structure of Retatrutide:

1)Triple Agonist Design
- GLP-1 receptor: Retatrutide delays gastric emptying, suppress appetite, and promote insulin secretion.
- GIP receptor: Retatrutide enhances insulin sensitivity and regulate central satiety signals.
- Glucagon receptor (GCGR): Retatrutide activates liver energy metabolism, promote lipolysis and glycogenolysis, and increase basal metabolic rate.
The triple synergistic effect increases energy consumption while reducing energy intake, significantly improving weight loss effects.

2) Structural Optimization
- Based on the GIP skeleton modification, non-natural amino acids (such as α-methylleucine at position 13) are introduced to enhance receptor affinity.
- The half-life is extended to 7 days through fatty acid side chain modification, supporting   once a week.